A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
BUSINESS
Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
RNAi pioneer Alnylam Pharmaceuticals is set to speed up its Japan business to eventually achieve double-digit annual growth in the country, looking to cash in on its expanding pipeline on top of two marketed and near-to-launch amyloidosis drugs, the company’s…
To read the full story
Related Article
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
- Alnylam Japan Taps Ex-Galderma Chief Yutaka Okada as New President
July 29, 2022
- Alnylam Seeks Japan Approval for Vutrisiran for FAP
December 21, 2021
- Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
BUSINESS
- Japan’s Big 4 Drug Wholesalers See Combined Profits Slip despite Sales Growth
November 13, 2026
- Pfizer Files Litfulo for Vitiligo in Japan
November 13, 2026
- Takeda Debuts Narcolepsy Drug Orzeyful in US after Japan, China
November 13, 2026
- Keytruda Holds Japan Sales Crown in July-September as Mounjaro Climbs: IQVIA
November 13, 2026
- Genmab Eyes Early Japan Launches for 2 Cancer Blockbuster Hopefuls
November 13, 2026
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…